Clinical Trial Update: Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age [Phase 4]

View source ↗

Summary

Phase 4 study assessing immunogenicity and safety of a TETRAXIM booster given to children aged 4-6 years.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• TETRAXIM (Diphtheria, Tetanus, Pertussis, Poliomyelitis, Haemophilus influenzae type b conjugate vaccine)

Snippet

Sponsor: Sanofi | Conditions: Diphtheria, Tetanus | Phase 4 | Status: COMPLETED